Back to TAKView Full LandscapeView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
10 competitors in Diabetes Mellitus, Type 2
NVOInsulin Glargine 100U/mL
Phase 3LLYHuman Insulin Inhalation Powder
Phase 3LLYInsulin lispro mix 25
Phase 3LLYDetemir
Phase 3NVOInsulin Icodec
Phase 3Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA9/18/2013
Vipidia
Vipidia is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
REPLAGALPhase 3
Fabry Disease
Alogliptin and pioglitazonePhase 3
Type 2 Diabetes Mellitus
HYQVIAPhase 3
Primary Immunodeficiency Diseases (PID)
IGSC 20% infusionPhase 3
Primary Immunodeficiency Disease
Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.Phase 3
Hypertension
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts